Literature DB >> 25888568

Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL).

Sabine Dondorf1, Alexandra Schrader2, Marco Herling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25888568      PMCID： PMC4400363          DOI： 10.1074/jbc.L115.644641

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


× No keyword cloud information.
  6 in total

Review 1.  Advances in the design of ITK inhibitors.

Authors:  Jean-Damien Charrier; Ronald M A Knegtel
Journal:  Expert Opin Drug Discov       Date:  2013-02-07       Impact factor: 6.098

2.  Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Authors:  Yiming Zhong; Shuai Dong; Ethan Strattan; Li Ren; Jonathan P Butchar; Kelsey Thornton; Anjali Mishra; Pierluigi Porcu; J Michael Bradshaw; Angelina Bisconte; Timothy D Owens; Erik Verner; Ken A Brameld; Jens Oliver Funk; Ronald J Hill; Amy J Johnson; Jason A Dubovsky
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

Review 3.  Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.

Authors:  L Vargas; A Hamasy; B F Nore; C I E Smith
Journal:  Scand J Immunol       Date:  2013-08       Impact factor: 3.487

4.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

Review 5.  T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.

Authors:  Kathrin Warner; Nicole Weit; Giuliano Crispatzu; Joan Admirand; Dan Jones; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

6.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Authors:  Mark J Kiel; Thirunavukkarasu Velusamy; Delphine Rolland; Anagh A Sahasrabuddhe; Fuzon Chung; Nathanael G Bailey; Alexandra Schrader; Bo Li; Jun Z Li; Ayse B Ozel; Bryan L Betz; Roberto N Miranda; L Jeffrey Medeiros; Lili Zhao; Marco Herling; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113
  6 in total
  3 in total

1.  Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Authors:  S Oberbeck; A Schrader; K Warner; D Jungherz; G Crispatzu; J von Jan; M Chmielewski; A Ianevski; H H Diebner; P Mayer; A Kondo Ados; L Wahnschaffe; T Braun; T A Müller; P Wagle; A Bouska; T Neumann; S Pützer; L Varghese; N Pflug; M Thelen; J Makalowski; N Riet; H J M Göx; G Rappl; J Altmüller; M Kotrová; T Persigehl; G Hopfinger; M L Hansmann; H Schlößer; S Stilgenbauer; J Dürig; D Mougiakakos; M von Bergwelt-Baildon; I Roeder; S Hartmann; M Hallek; R Moriggl; M Brüggemann; T Aittokallio; J Iqbal; S Newrzela; H Abken; M Herling
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

2.  Advances and Perspectives in the Treatment of T-PLL.

Authors:  Till Braun; Jana von Jan; Linus Wahnschaffe; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

3.  Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.

Authors:  Sami Mamand; Rebecca L Allchin; Matthew J Ahearne; Simon D Wagner
Journal:  Sci Rep       Date:  2018-09-21       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.